347 related articles for article (PubMed ID: 15051778)
1. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.
Auerbach M; Ballard H; Trout JR; McIlwain M; Ackerman A; Bahrain H; Balan S; Barker L; Rana J
J Clin Oncol; 2004 Apr; 22(7):1301-7. PubMed ID: 15051778
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment.
Mystakidou K; Kalaidopoulou O; Katsouda E; Parpa E; Kouskouni E; Chondros C; Tsiatas ML; Vlahos L
Anticancer Res; 2005; 25(5):3495-500. PubMed ID: 16101168
[TBL] [Abstract][Full Text] [Related]
4. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
5. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
Henry DH; Abels RI
Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients.
Auerbach M; Winchester J; Wahab A; Richards K; McGinley M; Hall F; Anderson J; Briefel G
Am J Kidney Dis; 1998 Jan; 31(1):81-6. PubMed ID: 9428456
[TBL] [Abstract][Full Text] [Related]
8. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
[TBL] [Abstract][Full Text] [Related]
9. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
10. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
[TBL] [Abstract][Full Text] [Related]
11. ITDI is the preferred treatment for iron supplementation in rHuEpo-treated anemic PD patients.
Ahsan N
Adv Perit Dial; 1998; 14():228-31. PubMed ID: 10649730
[TBL] [Abstract][Full Text] [Related]
12. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.
Heras P; Kritikos K; Hatzopoulos A; Mitsibounas D
Eur J Cancer Care (Engl); 2008 Nov; 17(6):619-23. PubMed ID: 18707619
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy.
Hedenus M; Näsman P; Liwing J
J Clin Pharm Ther; 2008 Aug; 33(4):365-74. PubMed ID: 18613854
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
Desai J; Demetri GD
Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
[TBL] [Abstract][Full Text] [Related]
16. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.
Straus DJ; Testa MA; Sarokhan BJ; Czuczman MS; Tulpule A; Turner RR; Riggs SA
Cancer; 2006 Oct; 107(8):1909-17. PubMed ID: 16977654
[TBL] [Abstract][Full Text] [Related]
17. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
18. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
Henry DH; Dahl NV; Auerbach M; Tchekmedyian S; Laufman LR
Oncologist; 2007 Feb; 12(2):231-42. PubMed ID: 17296819
[TBL] [Abstract][Full Text] [Related]
19. Clinical benefits of two different dosing schedules of recombinant human erythropoietin in anemic patients with advanced head and neck cancer.
Gupta S; Singh PK; Bhatt ML; Pant MC; Sundar S; Verma J; Paul S; Kumar D; Shah A; Gupta R; Negi MP
Biosci Trends; 2010 Oct; 4(5):267-72. PubMed ID: 21068481
[TBL] [Abstract][Full Text] [Related]
20. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
Bastit L; Vandebroek A; Altintas S; Gaede B; Pintér T; Suto TS; Mossman TW; Smith KE; Vansteenkiste JF
J Clin Oncol; 2008 Apr; 26(10):1611-8. PubMed ID: 18375890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]